Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c
August 5, 2021 4:28 PM EDTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.
We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is... More
